Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Oncology (Toronto, Ont.)|December 22, 2022
CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the LiteratureGiada Targato, Lucia Bortot, Arianna Dri, et al.
Breast (Edinburgh, Scotland)|December 21, 2024
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancerBrenno Pastò, Riccardo Vida, Arianna Dri, et al.
Journal of Clinical Medicine|June 24, 2022
Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of ResponseEnrico Zelin, Carlo Alberto Maronese, Arianna Dri, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-PracticeArianna Dri, Silvio Ken Garattini, Marika Cinausero, et al.
Skin Appendage Disorders|October 4, 2021
Breast Cancer-Related Neoplastic Alopecia: A Case Report and Review of the LiteratureRoberta Vezzoni, Ludovica Toffoli, Claudio Conforti, et al.
Journal of Chemotherapy (Florence, Italy)|February 12, 2026
Effectiveness of azacytidine for poly ADP-ribose polymerase inhibitor-induced myelodysplastic syndrome in ovarian cancer patient: a twofold triumphStefano Fucina, Riccardo Vida, Arianna Dri, et al.
Current Treatment Options in Oncology|March 16, 2021
Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell CarcinomaEnrico Zelin, Iris Zalaudek, Marina Agozzino, et al.
Cancers|September 13, 2025
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic ReviewGiuseppe Di Grazia, Arianna Dri, Angela Grieco, et al.
Cancer Treatment Reviews|December 20, 2023
Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)Arianna Dri, Grazia Arpino, Giampaolo Bianchini, et al.
International Journal of Molecular Sciences|April 14, 2026
LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer PatientsBianca Posocco, Diletta Pasin, Nicoletta De Cesaro, et al.
Pageof 2